How Side Effect Severity Influences Patient Treatment Choice in Multiple Myeloma - Dr. Hydren #ASH24
3:46
Daratumumab + Lenalidomide vs Lenalidomide Maintenance in Myeloma | Laahn Foster, MD | #ASH24
3:46
Can Mass-Fix Replace Bone Marrow Biopsy? | Angela Dispenzieri, MD | #ASH24
6:42
Dara-CyBorD vs CyBorD in Newly Diagnosed AL Amyloidosis| Hans Lee, MD | #ASH2024
2:44
Frailty’s Impact on Outcomes in Older MM Patients Treated with Bispecifics | Nadine Abdallah| #ASH24
3:54
Post-CAR-T Driving Restrictions after Week 4 In Myeloma Appear Unnecessary | Rahul Banerjee | #ASH24
3:19
Understanding the ASH Research Collaborative- COSMIC Study | Saad Usmani, MD | #ASH24
3:33
24-hour Urine Testing Does Not Add Value to Myeloma Response Assessments | Rahul Banerjee | #ASH24
2:45